From The Editor

  1. From BPI West: A Roundtable Discussion On Continuous Manufacturing 4/14/2025

    Process Development experts share their thoughts on continuous manufacturing at this year's BPI West, touching on its benefits and present barriers to adoption.

  2. From BPI West: Key Challenges And Benefits Of Continuous Manufacturing 4/7/2025

    Continuous manufacturing was a hot topic of conversation at this year's BPI West. AstraZeneca's Ken Lee, Ph.D., weighs in during an exclusive interview with Bioprocess Online.

  3. From BPI West: An Upstream Scientist's Advice On Target Glycosylation 4/1/2025

    Bioprocess Online spoke to an upstream scientist at Bristol Myers Squibb during this year's BPI West. Here's what he had to say.

  4. 2025 Cell Therapy Outlook From BPI West 3/31/2025

    Bioprocess Online and Cell & Gene spoke with Takeda’s Amy Shaw at BPI West to discuss the industry and her key takeaways from the conference.

  5. Using AI And ML To Gain Insight Into Optimal Glycoforms 3/28/2025

    Bioprocess Online asked Nathan Lewis, Ph.D., to briefly explain the research he presented at BPI West 2025.

  6. Impressions And Takeaways From BPI West 2025 3/27/2025

    Editor Tyler Menichiello reviews the most compelling topics and sessions from this year's BioProcess International U.S. West.

  7. Areas For Advancement In Peptide Manufacturing 2/27/2025

    Experts from Eli Lilly, NervGen, and Piramal Pharma Solutions discuss the myriad of ways peptide manufacturing can be improved, drawing on years of industry experience and insight.

  8. For Gilead, Sustainability Is More Than A PR Effort 2/14/2025

    Gilead's chief sustainability officer and SVP of operations, Joydeep Ganguly, explains the company's cultural focus on sustainability and how it influences everything from R&D to manufacturing. 

  9. GlycoNex On Challenges In Biosimilar Development, Manufacturing 1/29/2025

    In this written Q&A, GlycoNex president and CEO, Dr. Mei-Chun Yang, shares insight into the company's development of its denosumab biosimilar, SPD8. She covers the company’s approach to analytics, cell line development, scaling, and more.

  10. Easing Autologous Cell Collection, Automating Manufacturing 1/22/2025

    To circumvent the challenges of leukapheresis, CellProthera developed a novel method for collecting therapeutic stem cells from whole blood. CSO Ibon Garitaonandia, Ph.D., discusses the company's mission to streamline manufacturing.